AstraZeneca Pharma India Limited

Equities

ASTRAZEN

INE203A01020

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
5,320 INR +0.01% Intraday chart for AstraZeneca Pharma India Limited +5.81% -3.61%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India CI
Astrazeneca Pharma India Limited Announces Board Changes CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
AstraZeneca Pharma India Limited Announces Board Changes CI
AstraZeneca Pharma India Limited Announces Directorate Appointments CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion MT
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024 MT
India's Nifty set for muted open after steep drop RE
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive) CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab MT
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab CI
AstraZeneca Pharma India Limited Announces Management Changes CI
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director CI
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head ­ Oncology with Effect from November 1, 2023 CI
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023 CI
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
AstraZeneca Pharma Launches Neurofibromatosis Type 1 Drug in India MT
AstraZeneca Pharma India Limited Announces Launch of Selumetinib 10 Mg and 25 Mg Capsule CI
AstraZeneca Pharma India Limited Announces Executive Changes CI
AstraZeneca Pharma India Limited Proposes to Declare Dividend for the Financial Year 2022-23 CI
AstraZeneca Gets Regulatory Nod to Import Tremelimumab (Imjudo) Concentrate MT
Astrazeneca Pharma India Names CFO MT
AstraZeneca Pharma India Limited Announces Retirement of Mr. Rajesh Marwaha from the Office of Whole-Time Director, Effective September 30, 2023 CI
Chart AstraZeneca Pharma India Limited
More charts
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; oncology, and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacturing, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings